Urinary tract infection (UTI) is the second most common infectious disease, affecting 150 million people worldwide annually. Most of the patients are women. CTG01 provides a new approach to preventing or even treating uropathogenic Escherichia coli infections by reducing bacterial adherence to host cells. Since CTG02 is not an antibiotic, there will be no issue of antibiotic resistance in the future.

Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases, with around 2 million new cases diagnosed globally each year. China contributes 40% of these cases. CTG02 is a third-generation epidermal growth factor receptor inhibitor, and it can be developed as a small molecule targeted therapy for non-small cell lung cancer.Compared to Osimertinib, CTG02 has improved pharmacokinetic, therapeutic, and toxicological characteristics. 

CTG03 is an IDO1 inhibitor. By inhibiting IDO1 in tumor cells and reducing indoleamine 2,3-dioxygenase (IDO), CTG03 can restore and promote the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer cells (NK cells), and T lymphocytes. This leads to tumor reduction.

CTG04 is an IDO1 inhibitor that can be used as a standalone therapy or in combination with other drugs. It can be developed as a novel class of medications for the treatment of various cancers, including non-small cell lung cancer, bladder cancer, melanoma, and more.

CTG05 provides a new chemical entity that can be used to treat lysosomal storage diseases. The lysosome is a cellular organelle that contains various hydrolytic enzymes used to break down cellular waste, such as proteins, nucleic acids, carbohydrates, and more. Lysosomal dysfunction caused by gene mutations will lead to the inability to break down cellular waste. As a result, the accumulation of cellular waste will lead to disease. Lysosomal dysfunction can lead to over 70 rare genetic disorders, which are collectively referred to as lysosomal disease. Examples include Gaucher's disease, Fabry's disease, and Parkinson's disease.

CTG06 is a new chemical entity that provides a treatment option for joint and muscle sprains. It has improved pharmacokinetic, therapeutic, and toxicological properties compared to methocarbamol, a central muscle relaxant used to treat skeletal muscle spasms and conditions such as joint and muscle sprains, lumbar strain, and sciatica.

CTG07 is an HCN channel blocker that can be used to reduce the risk of hospitalization for worsening heart failure in adult patients and to treat stable symptomatic heart failure caused by dilated cardiomyopathy in pediatric patients.

CTG08 is a selective serotonin receptor agonist for 1b and 1d subtypes, which can be developed as a new chemical entity for the treatment of migraine. Migraine is typically accompanied by nausea, vomiting, and extreme sensitivity to light and sound, and can cause severe throbbing or pulsing pain.

CTG09, a Janus kinase (JAK) inhibitor, acts on the immune system and can be used to treat moderate to severe active rheumatoid arthritis, ulcerative colitis, and other related diseases.

CTG10 is an inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH1 functions by reducing the abnormal production of the oncogenic metabolite 2-hydroxyglutarate, leading to malignant cell differentiation.

CTG11 is a farnesoid X receptor (FXR) agonist. FXR inhibits cholesterol synthesis, reduces the concentration of bile acids in liver cells, and promotes bile secretion, thereby reducing the exposure of the liver to bile acids.

CTG12 inhibits the growth of both androgen-dependent and androgen-independent prostate cancer cells. CTG12 can be developed as a potential novel drug for treating hormone-sensitive and hormone-refractory prostate cancer with minimal side effects.

CTG13 is a technology that applies cytokines for the early detection of tumors. After simple processing, human serum can be directly used in enzyme-linked immunosorbent assay (ELISA) to determine the presence of tumor cells in the human body through colorimetric and fluorescence detection.

CTG14 is a phosphoinositide 3-kinase (PI3K) inhibitor that blocks the P110δ, the subtype of PI3K. It can be developed to treat relapsed chronic lymphocytic leukemia (CLL).

CTG15 reduces fibroblast proliferation, inhibits collagen production stimulated by transforming growth factor β, and decreases the production of fibrogenic mediators. AI calculations indicate that CTG15 may be utilized in the treatment of idiopathic pulmonary fibrosis.

CTG16 is a synthetic flavonoid compound with the ability to penetrate the brain and activate receptors (TrkB) that facilitate neuronal growth. Experimental findings indicate that CTG16 may possess certain cognitive and motor advantages. Thus, CTG16 can be developed as a potential nootropic agent.